XML 39 R25.htm IDEA: XBRL DOCUMENT
v3.25.4

Nature of Operations and Summary of Significant Accounting Policies (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2025
Accounting Policies [Abstract] |
Schedule of Franchisor Disclosure | The following table summarizes the number of clinics in operation under franchise agreements and as company-owned or managed for the years ended December 31, 2025 and 2024. All company-owned or managed clinics operations are recorded as discontinued operations:
| Year Ended December 31,
Franchised clinics: | 2025 |  | 2024
Clinics open at beginning of year | 842 |  |  | 800 |
Opened during the year | 29 |  |  | 57 |
Acquired during the year | 41 |  |  | 3 |
Sold during the year | — |  |  | — |
Closed during the year | (27) |  |  | (18) |
Clinics in operation at the end of the year | 885 |  |  | 842 |
| Year Ended December 31,
Company-owned or managed clinics: | 2025 |  | 2024
Clinics open at beginning of year | 125 |  |  | 135 |
Opened during the year | — |  |  | — |
Acquired during the year | — |  |  | — |
Sold during the year | (41) |  |  | (3) |
Closed during the year | (9) |  |  | (7) |
Clinics in operation at the end of the year | 75 |  |  | 125 |
Total clinics in operation at the end of the year | 960 |  |  | 967 |
Clinic licenses sold but not yet developed | 82 |  |  | 92 |
Executed letters of intent for future clinic licenses | 57 |  |  | 53 |
Schedule of Variable Interest Entities | VIE net income (including the management fee) for the years ended December 31, 2025 and 2024 is included in Income (loss) from discontinued operations before income tax expense and income tax expense from discontinued operations in the consolidated income statements as follows:
| Year Ended December 31,
| 2025 |  | 2024
Income from discontinued operations before income tax expense | 1,011,689 |  |  | 1,641,325 |
Income tax expense from discontinued operations | 25,207 |  |  | 210,263 |
Net income | 986,482 |  |  | 1,431,062 |
The carrying amount of the VIEs’ assets and liabilities is included in discontinued operations as of December 31, 2025 and 2024 in the consolidated balance sheets as follows:
| December 31, 2025 |  | December 31, 2024
Discontinued operations current assets | $ | 994,138 |  |  | $ | 1,087,203 |
Discontinued operations current liabilities | 6,079,903 |  |  | 7,125,071 |
Schedule of Reconciliation of Accounts Receivable Allowance for Credit Losses | The following table provides a rollforward of the activity related to our allowance for credit losses:
| Allowance for credit losses
Balance at December 31, 2023 | $ | — |
Bad debt expense recognized during the year | 220,893 |
Write-off of uncollectible amounts | — |
Balance at December 31, 2024 | $ | 220,893 |
Bad debt expense recognized during the year | 286,232 |
Write-off of uncollectible amounts | (77,638) |
Balance at December 31, 2025 | $ | 429,487 |
Schedule of Net Loss (Gain) on Disposition or Impairment Related to Continuing Operations | During the year ended December 31, 2024, certain long-lived asset groups were determined to not be recoverable and were written down from their carrying values to their respective fair values resulting in the following non-cash impairment losses which are included in Net loss on disposition or impairment related to continuing operations. Net impairment losses on long-lived assets were not material for the year ended December 31, 2025.
| Year Ended December 31, 2024
| Carrying Value |  | Fair Value |  | Net loss on disposition or impairment related to continuing operations
Property and equipment, net | $ | 57,959 |  |  | $ | 40,872 |  |  | $ | 17,087 |
Operating lease right-of-use asset | 703,682 |  |  | 667,314 |  |  | 36,368 |
Intangible assets, net | 12,564 |  |  | — |  |  | 12,564 |
Total Net loss on disposition or impairment related to continuing operations |  | $ | 66,019 |
Schedule of Impairment Losses and Disposal Gains and Losses Recorded in (Loss) Income from Discontinued Operations | During the year ended December 31, 2024, certain long-lived asset groups classified as held and used were determined to not be recoverable were written down from their carrying values to their respective fair values resulting in the following non-cash impairment losses which are included in Income (loss) from discontinued operations before income tax expense in the consolidated income statements.
| Year Ended December 31, 2024
| Carrying Value |  | Fair Value |  | Net loss on disposition or impairment related to discontinued operations
Property and equipment, net | $ | 3,929,036 |  |  | $ | 2,755,318 |  |  | $ | 1,173,718 |
Operating lease right-of-use asset | 5,779,712 |  |  | 4,347,457 |  |  | 1,432,255 |
Intangible assets, net | 298,510 |  |  | 252,746 |  |  | 45,764 |
Total Net loss on disposition or impairment related to discontinued operations |  | $ | 2,651,737 |
As a result of its evaluation of the recoverability of the carrying value of the assets and liabilities held for sale relative to the clinics estimated fair values, we recorded an estimated net loss on disposal, which is included in Income (loss) from discontinued operations before income tax expense in the consolidated income statements:
|  | Year Ended December 31,
|  | 2025 |  | 2024
Net loss on disposition or impairment related to discontinued operations |  | $ | 2,734,726 |  |  | $ | 4,540,530 |
The following table shows the composition of our impairment losses and disposal gains and losses recorded in Income (loss) from discontinued operations before income tax expense for the years ended December 31, 2025 and 2024:
|  | Year Ended December 31,
|  | 2025 |  | 2024
Impairment on long-lived assets held for use |  |  |  |
Property and equipment, net |  | $ | — |  |  | $ | 1,173,718 |
Operating lease right-of-use asset |  | — |  |  | 1,432,255 |
Intangible assets, net |  | — |  |  | 45,764 |
Impairment on assets held for sale |  |  |  |
Assets held for sale |  | 2,734,726 |  |  | 4,540,530 |
Loss on disposal of assets other than by sale |  |  |  |
Property and equipment, net |  | 383,311 |  |  | 161,057 |
Operating lease right-of-use asset |  | 1,396,870 |  |  | 406,038 |
Loss (gain) on the sale of assets |  | 926,103 |  |  | (44,807) |
Total net loss on disposition or impairment related to discontinued operations |  | $ | 5,441,010 |  |  | $ | 7,714,555 |
The key components of Net income (loss) from discontinued operations that were included in our consolidated income statements are as follows:
| Year Ended December 31,
| 2025 |  | 2024
Revenues: |  |  |
Revenues from company-owned or managed clinics | $ | 54,038,508 |  |  | $ | 69,982,344 |
Total revenues | 54,038,508 |  |  | 69,982,344 |
Cost of revenues: |  |  |
IT cost of revenues | 20,971 |  |  | 47,817 |
Total cost of revenues | 20,971 |  |  | 47,817 |
Selling and marketing expenses | 5,755,830 |  |  | 7,850,616 |
Depreciation and amortization | 69,558 |  |  | 3,350,748 |
General and administrative expenses | 39,450,918 |  |  | 54,988,780 |
Total selling, general and administrative expenses | 45,276,306 |  |  | 66,190,144 |
Net loss on disposition or impairment from discontinued operations | 5,441,010 |  |  | 7,714,555 |
Income (loss) from discontinued operations | 3,300,221 |  |  | (3,970,172) |
Other expense, net | 99,592 |  |  | 2,114 |
Income (loss) before income tax expense | 3,200,629 |  |  | (3,972,286) |
Income tax expense from discontinued operations | 25,207 |  |  | 210,263 |
Net income (loss) from discontinued operations | $ | 3,175,422 |  |  | $ | (4,182,549) |
The following table summarizes the major classes of assets and liabilities of discontinued operations that were included in our consolidated balance sheets:
| December 31, 2025 |  | December 31, 2024
ASSETS |  |  |
Accounts receivable | $ | 315,201 |  |  | $ | 2,484,248 |
Prepaid expenses and other assets | 581,504 |  |  | 549,605 |
Assets held for sale | 20,051,965 |  |  | 38,395,986 |
Property and equipment, net | 67,779 |  |  | 208,074 |
Deferred tax assets (attributable to VIEs) | 994,138 |  |  | 1,087,204 |
Deposits and other assets | 235,731 |  |  | 425,938 |
Total assets, discontinued operations | $ | 22,246,318 |  |  | $ | 43,151,055 |
LIABILITIES |  |  |
Accounts payable | $ | 83,503 |  |  | $ | 67,107 |
Accrued expenses | 2,519,433 |  |  | 5,066,941 |
Payroll liabilities ($0.6 million and $0.9 million attributable to VIEs, respectively) | 988,865 |  |  | 2,333,335 |
Operating lease liability | 651,844 |  |  | 153,517 |
Finance lease liability | — |  |  | 38,015 |
Other current liabilities (attributable to VIEs) | 756,483 |  |  | 1,079,441 |
Liabilities to be disposed of ($4.7 million and $5.2 million attributable to VIEs, respectively) | 16,368,318 |  |  | 28,629,103 |
Total liabilities, discontinued operations | $ | 21,368,446 |  |  | $ | 37,367,459 |
The key components of cash flows from discontinued operations are as follows:
| Year Ended December 31,
| 2025 |  | 2024
Significant operating and investing non-cash items |  |  |
Depreciation and amortization | $ | 69,558 |  |  | $ | 3,350,748 |
Net loss on disposition or impairment | 5,441,010 |  |  | 7,714,555 |
Capital expenditures |  |  |
Purchase of property and equipment | 84,256 |  |  | 664,423 |
The principal components of the held for sale assets and liabilities to be disposed of as of December 31, 2025 and 2024 were as follows:
| December 31, 2025 |  | December 31, 2024
ASSETS |  |  |
Property and equipment, net | $ | 4,497,545 |  |  | $ | 8,457,627 |
Operating lease right-of-use asset | 14,111,081 |  |  | 19,643,917 |
Intangible assets, net | 4,288,265 |  |  | 6,906,807 |
Goodwill | 3,482,718 |  |  | 8,459,238 |
Valuation allowance | (6,327,644) |  |  | (5,071,603) |
Total assets held for sale | $ | 20,051,965 |  |  | $ | 38,395,986 |
LIABILITIES |  |  |
Operating lease liability | $ | 11,065,542 |  |  | $ | 20,526,714 |
Deferred revenue from company-owned or managed clinics | 5,302,776 |  |  | 8,102,389 |
Total liabilities to be disposed of | $ | 16,368,318 |  |  | $ | 28,629,103 |
Schedule of Earnings (Loss) per Common Share |
| Year Ended December 31,
| 2025 |  | 2024
Net loss from continuing operations | $ | (268,157) |  |  | $ | (1,614,344) |
Net income (loss) from discontinued operations | 3,175,422 |  |  | (4,182,549) |
Net income (loss) | $ | 2,907,265 |  |  | $ | (5,796,893) |
Weighted average common shares outstanding — basic | 15,134,215 |  |  | 14,919,091 |
Effect of dilutive securities: |  |  |
Unvested restricted stock and stock options | 52,653 |  |  | 228,156 |
Weighted average common shares outstanding — diluted | 15,186,868 |  |  | 15,147,247 |
Earnings (loss) per share: |  |  |
Basic earnings (loss) per share: |  |  |
Continuing operations | $ | (0.02) |  |  | $ | (0.11) |
Discontinued operations | 0.21 |  |  | (0.28) |
Net earnings (loss) per share | 0.19 |  |  | (0.39) |
Diluted earnings (loss) per share |  |  |
Continuing operations | $ | (0.02) |  |  | $ | (0.11) |
Discontinued operations | 0.21 |  |  | (0.28) |
Net earnings (loss) per share | 0.19 |  |  | (0.38) |
Potentially dilutive securities excluded from the calculation of diluted net income (loss) per common share as the effect would be anti-dilutive were as follows:
| Year Ended December 31,
| 2025 |  | 2024
Stock options | 71,030 |  |  | 87,651 |

X
- References No definition available. + Details
Name: | us-gaap_AccountingPoliciesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of allowance for credit loss on accounts receivable. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13 + Details
Name: | us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure for impairment of long-lived assets held and used by an entity which includes a description of the impaired long-lived asset and facts and circumstances leading to the impairment, aggregate amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired long-lived asset is reported. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.CC) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2 + Details
Name: | us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 3 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3A Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4A Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5D -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5D Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7 Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1 Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3 + Details
Name: | us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of franchisors that are included in the discussion of the nature of an entity's operations. + References No definition available. + Details
Name: | us-gaap_ScheduleOfFranchisorDisclosureTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 5A -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-5A Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-9 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-4 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-6 + Details
Name: | us-gaap_ScheduleOfVariableInterestEntitiesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration